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Abstract  
Background: 
Circulating insulin-like growth factor binding protein 3 (IGFBP-3) has been associated with PCa. 
Preclinical studies found that vitamin D regulates IGFBP-3 expression, although evidence from 
epidemiological studies are conflicting. 
Methods:  
Mendelian Randomisation analyses (MR) were conducted to reassess associations between IGFBP-3 
and Prostate cancer (PCa) risk and advanced PCa using summary statistics from the PRACTICAL 
consortium (44,825cases;27,904controls). Observational and MR analyses were conducted to assess 
the relationship between inactive vitamin D (25(OH)D) and IGFBP-3 using data from the ProtecT study 
(1,366cases;1,071controls) and summary statistics from the CHARGE consortium (n=18,995). 
Results: 
The odds ratio (OR) for PCa per standard deviation (SD) unit increase in circulating IGFBP-3 was 
1.14(95%CI:1.02-1.28). The OR for advanced PCa per SD unit increase in IGFBP-3 was 
1.22(95%CI:1.07-1.40). Observationally, a SD increase in 25(OH)D was associated with a 
0.1SD(95%CI:0.05, 0.14) increase in IGFBP-3. MR analyses found little evidence for a causal 
relationship between circulating 25(OH)D and IGFBP-3 in the circulation. 
 
Conclusions:  
This study provided confirmatory evidence that IGFBP-3 is a risk factor for PCa risk and progression. 
Observationally, there was evidence that 25(OH)D is associated with IGFBP-3, but MR analyses 
suggested that these findings were unlikely to be causal. Findings may be limited by the nature of 
instrumentation of 25(OH)D and IGFBP-3 and the utility of circulating measures. 25(OH)D appears 
unlikely to be causally related to IGFBP-3 in the circulation, however, our findings do not preclude 
causal associations at the tissue level. 
 
Impact:  
IGFBP-3 is a PCa risk factor but 25(OH)D are unlikely to be causally related to IGFBP-3 in the 
circulation. 
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Introduction 
Insulin-like growth factor binding protein 3 (IGFBP-3) is the most abundant circulating IGFBP and 
modulates the bioactivity of IGFs1. Independent of IGFs, IGFBP-3 regulates cell proliferation, leading 
to increased interest in its role in carcinogenesis2. A meta-analysis found that circulating IGFBP-3 was 
associated with increased odds of Prostate cancer (PCa) (OR for highest versus lowest quintile: 
1.25;95%CI:1.12,1.40)3. This is in line with results from a nested case-control study within the Prostate 
Testing for Cancer and Treatment (ProtecT) trial, which found evidence that circulating IGFBP-3 was 
associated with increased PCa odds (OR: 1.28 per SD increase in IGFBP-3; 95%CI:1.21,1.36)4. There 
is inconsistent evidence regarding the association between circulating IGFBP-3 and aggressive PCa. 
However, a Mendelian randomization (MR) study concluded that the IGFs may be associated with 
more aggressive PCa, in particular IGFBP-35. 
 
Active vitamin D (1,25-hydroxyvitamin D;1,25(OH)2D) up-regulates IGFBP-3 expression by binding to 
the vitamin D receptor which in turn binds to the vitamin D response element in the IGFBP-3 
promoter6,7. In the context of this relationship, there is motivation to assess the relationship between 
IGFBP-3 and the inactive form of vitamin D (25-hydroxyvitamin D;25(OH)D), as it acts as a proxy for 
1,25(OH)2D and is the most likely form of supplementation8,9. Evidence from observational studies 
examining the direct association between circulating 25(OH)D and 1,25(OH)2D with PCa incidence 
and progression been inconclusive10. However, there is evidence that SNPs in vitamin D pathway are 
associated with higher PCa grade11. Despite this, a recent MR study using single nucleotide 
polymorphisms (SNPs) (representing lower 25(OH)D) failed to provide evidence of a causal 
association between 25(OH)D and risk of 7 types of cancers including PCa12. Currently, it is unlikely 
that 25(OH)D exerts large linear effects on PCa, but small or non-linear effects cannot be ruled out13. 
Indeed, preclinical studies have suggested that a possible mechanism for a vitamin D effect could be 
through the regulation of IGFBP-314-16.  
 
Evidence from observational studies investigating the association between circulating 25(OH)D and 
IGFBP-3 has been conflicting. To compound this, observational studies can suffer from the effects of 
confounding, bias and reverse causation17-20. Specifically reverse causation could exist as IGFBP-3 
can affect 25(OH)D through its effect on IGF-I and residual confounding might be present due to 
inadequate control for confounders such as BMI. Further examination of the relationship between 
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25(OH)D and IGFBP-3 is needed to clarify if vitamin D affects cancer via IGFBP-3.  
 
Mendelian randomization (MR), which uses genetic variants as proxies of an exposure, is a causal 
analysis method used to investigate causality between exposures and health outcomes. Associations 
between SNPs and outcomes can provide evidence of causation since they are not subjected to bias 
(i.e.,reverse causation and confounding) found in observational studies21. Recently, two meta-
analyses of Genome-Wide Association Studies (GWAS) identified SNPs associated with circulating 
IGFBP-322 and 25(OH)D23, respectively. The SNPs associated with circulating IGFBP-3 and 25(OH)D 
provide a framework to assess the consequence of lifelong 25(OH)D on IGFBP-3 independent of other 
factors.  
 
In this study, we aimed to re-assess the causal relationship between IGFBP-3 and PCa. We also 
aimed to undertake both observational and one-sample MR analyses within ProtecT to assess the 
observational and causal relationship between 25(OH)D and IGFBP-3 and to compare these in order 
to assess the impact of potential bias, confounding or reverse causality. We also aimed to investigate 
whether there is a causal effect of 25(OH)D on IGFBP-3 using two-sample MR in independent data 
from the IGF working group of the CHARGE consortium.  
 
Methods and Materials 
Study Design  
This investigation had three components (Figure 1): 1) two-sample MR analyses were conducted to 
reassess the causal relationship between IGFBP-3 and PCa risk and advanced PCa (Gleason≥8, 
death from PCa, PSA>100 or metastasis) using summary statistics from the PRACTICAL consortium; 
2) linear regression analyses were conducted to investigate the observational relationship between 
circulating 25(OH)D and IGFBP-3 using individual level data from ProtecT; and 3) one-sample MR 
analyses using individual level data from ProtecT and two-sample MR analyses24,25 using summary 
statistics from the IGFBP-3 GWAS were conducted to investigate the causal relationship between 
25(OH)D and IGFBP-3.  
 
Study populations and data sources for observational and MR analyses 
Individual level analyses (observational and one-sample MR) were examined in a nested case-control 
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study within the ProtecT trial26,27 (details of the cohort are described in the Supplementary methods). 
For the observational analyses, 1,446 cases and 1,449 controls with 25(OH)D and IGFBP-3 measured 
at diagnosis and before treatment were included. Circulating 25(OH)D in blood plasma was measured 
using tandem mass spectrometry, as described previously28. Circulating 1,25(OH)2D were measured 
in blood plasma using immunoassay, as previously described29. Circulating IGFBP-3 in blood serum 
was measured using in-house radioimmunoassay, as previously described4 (see Supplementary 
methods). Seasonality in 25(OH)D and 1,25(OH)2D levels were adjusted using the cosinor method as 
previously described30. This method was chosen instead of adjusting models for season of blood draw, 
as it is a more accurate way to assess an individual’s vitamin D status31. Details of how potential 
confounders (BMI, exercise, smoking, alcohol consumption, family history of PCa, history of benign 
prostatic hyperplasia, diabetes, social class and ethnicity) were measured are provided in the 
Supplementary methods. Genome-wide genotyping of participants was carried out using the Illumina 
Human660W array (see Supplementary methods). Altogether, 674 cases and 410 controls with 
genotype data and IGFBP-3 measured were included in the one-sample MR analyses.  
 
A previous MR study5 had investigated the association between the IGF axis with risk of PCa by 
identifying SNPs associated with the IGFs from a GWAS for IGFBP-332 (n=10,018) and candidate 
gene studies and using summary statistics from a PCa risk GWAS (n=22,898 cases and 23,054 
controls) genotyped using the iCOGS array. A new GWAS for risk of PCa33 (n=44,825 cases and 
27,904 controls) genotyped using Oncoarray and an up-dated GWAS for IGFBP-322 (n=18,995) were 
recently published. We up-dated the previous MR analysis for IGFBP-3 and risk of PCa using the 
latest PCa GWAS meta-analysis33 and the latest IGFBP-3 GWAS meta-analysis22 (see 
Supplementary methods). For our MR analyses investigating the causal relationship between 
25(OH)D and IGFBP-3, we used the following summary statistics:  1) IGFBP-3 GWAS22 conducted by 
the IGF working group of the CHARGE consortium (n=18,995); and 2) 25(OH)D GWAS34 (n=79,366) 
conducted by the SUNLIGHT consortium (see Supplementary methods).  
 
Identification of genetic instruments for MR analyses 
Instruments for IGFBP-3 
The previous MR study5 investigating the causal relationship between IGFs and PCa used individual 
SNPs identified either by the discovery IGF GWAS32 or by candidate gene studies. For our MR 
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analyses, we constructed a new instrument for IGFBP-3 by selecting four independent IGFBP-3 
associated SNPs (rs11977526, rs700753, rs1065656, rs4234798) identified by the up-dated IGFBP-3 
GWAS22. rs700753 was not present in the 1000 genomes imputation reference used in the PCa 
GWAS. We identified a proxy SNP, rs700752, which was in high linkage disequilibrium (r2>0.8) using 
SNAP (https://www.broadinstitute.org/mpg/snap/).  
 
Instruments for 25(OH)D 
To-date, GWAS studies23,35,36 have focused on identifying SNPs associated with 25(OH)D as it is more 
stable than 1,25(OH)2D in the circulation. The latest 25(OH)D GWAS meta-analysis34 conducted in 
Europeans identified 2 novel loci (SEC23A (rs8018720) and AMDHD1 (rs10745742)) with a genome-
wide significant association with 25(OH)D and confirmed 4 previously identified loci23 
(CYP2R1(rs10741657);DHCR7(rs12785878);GC(rs3755967);and CYP24A1(rs17216707)) located in 
or near genes involved in 25(OH)D synthesis and metabolism. We constructed an instrument for 
25(OH)D (allele score) by using the six 25(OH)D-associated SNPs. As sensitivity analyses, we 
constructed a synthesis (rs12785878 and rs10741657) and metabolism (rs3755967 and rs17216707) 
score using SNPs in genes involved in 25(OH)D synthesis and metabolism.   
 
Statistical analyses 
Causal association between IGFBP-3 with overall cancer risk and advanced PCa   
SNP-exposure (IGFBP-3) and SNP-outcome (PCa) estimates for the four IGFBP-3 associated SNPs 
were combined using inverse-variance weighted (IVW) and maximum likelihood method to provide a 
weighted average of the causal estimates37. The previous MR study found that SNPs associated with 
IGFBP-3 have pleiotropic effects on other biomarkers of the IGF pathway5. The latest IGF GWAS 
found that two IGFBP-3 associated SNPs (rs700753 and rs1065656) were also associated with IGF-I 
at genome-wide significant levels22. To account for the effect of the IGFBP-3 associated SNPs on IGF-
I, we employed Multivariable MR, a new MR method that estimates causal effects using multiple SNPs 
associated with multiple exposures simultaneously38,39. Multivariable MR was conducted by regression 
of the SNP-PCa estimates on SNP-IGFBP-3 and SNP-IGF-I estimates in a multivariable weighted 
regression model. As the IGF GWAS did not analyse other IGFs, the multivariable MR method could 
not take into account the association between SNPs and other biomarkers of the IGF pathway. 
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Observational relationship between circulating 25(OH)D and IGFBP-3 in ProtecT  
Observational associations between 25(OH)D and IGFBP-3 were assessed using linear regression for 
cases and controls combined into one cohort or stratified by case-control status. Additional analyses 
were adjusted for potential confounders (age, centre, bmi, smoking and diabetes status). Associations 
of 25(OH)D and IGFBP-3 with potential confounders (listed above) were estimated using linear 
regression. Potential non-linear effects of 25(OH)D and IGFBP-3 were tested by carrying out linear 
regression with quadratic terms. Details of the analysis investigating the observational relationship 
between circulating 1,25(OH)2D and IGFBP-3 in ProtecT are provided in the Supplementary 
methods.  
 
Causal associations between 25(OH)D and IGFBP-3: one-sample MR in ProtecT   
A weighted genetic risk score (GRS) for 25(OH)D was generated by taking the sum of genotypes 
(coded 0,1,2) multiplied by the strength of the effect of each SNP on 25(OH)D recorded by the 
25(OH)D GWAS23. Two-stage least squares analyses using the weighted GRS was used to obtain 
estimates of the associations between season-adjusted 25(OH)D and IGFBP-340,41. The properties of 
the 25(OH)D-associated SNPs as instruments were assessed in ProtecT by examination of: i) first 
stage F-statistic (measure of the strength of the association between the instrument and exposure) 
and ii) associations of the SNPs with potential confounders. The first-stage F-statistic was obtained 
from the regression of 25(OH)D on the 25(OH)D genetic instrument (first stage of the two-stage least 
squares MR analysis). Sensitivity analyses were also performed by combining the estimates from 
SNPs involved in the synthesis and metabolism of vitamin D separately. We compared the 
instrumental variable estimates with those from observational analyses using the Durbin form of the 
Durbin-Wu-Hausman statistic42.  
 
Causal associations between 25(OH)D and IGFBP-3: two-sample MR  
The SNP-exposure (25(OH)D) and SNP-outcome (IGFBP-3) estimates for the six 25(OH)D associated 
SNPs were combined using the IVW method37. The IVW method (similar method to that used in the 
two-sample MR analysis of IGFBP-3 and PCa) is equivalent to the two-stage least square analyses 
using data from ProtecT43. Sensitivity analyses were performed by combining the estimates from 
SNPs involved in the synthesis and metabolism pathways separately.  As only a small number of 
SNPs were included in our MR analyses, methods to test for pleiotropy such as MR-Egger 
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regression43, weighted median44 and mode method45 were not conducted as these lack power with 
small number of SNPs. A leave-one-out analysis, which repeats the MR analysis by leaving out each 
SNP in turn, was applied to assess whether any single SNP was driving the causal estimate. In the 
reverse direction, we investigated the causal effect of IGFBP-3 on 25(OH)D using the two-sample MR 
analyses (see Supplementary methods).  
 
Power  
Power for one-sample MR analyses to detect the causal effect of 25(OH)D on IGFBP-3 was estimated 
using the online tool (http://glimmer.rstudio.com/kn3in/mRnd/)46, specifying alpha=0.05, R2=0.0535 and 
using the observational estimates from the ProtecT sample set. Given a sample size of 1134, in one-
sample MR, a causal effect of 0.39 SD units per SD unit change in 25(OH)D was required to yield 
80% power. For two-sample MR analysis of the same relationship, power to detect the causal effect of 
25(OH)D on IGFBP-3 was estimated using the “pwr.r.test” function (implemented in the pwr package 
in R) specifying alpha=0.05. The correlation between 25(OH)D and IGFBP-3 was obtained by taking 
the square-root of the variance in IGFBP-3 explained by the 25(OH)D associated SNPs. Given a 
sample size of 18,995 in the two-sample MR analysis, a causal effect needed to yield 80% power is 
0.09 SD units. This method is not dissimilar to that suggested elsewhere noting that power in a two-
sample procedure is limited by the direct SNP-outcome association47. All analyses were performed in 
R (version 3.0.1), Stata version 14 (Stata Corp) and using MR-Base (www.mrbase.org).  
 
Results 
Association between IGFBP-3 with overall cancer risk and advanced PCa   
In agreement with the previous MR of IGFBP-3 and PCa5, two-sample MR analyses using the latest 
PCa GWAS found that the OR for PCa per SD unit increase in circulating IGFBP-3 was 1.12 
(95%CI:0.91-1.36;p=0.18) from IVW analyses. The multivariable estimate, which took into account the 
effect of the SNPs on IGF-I, was of similar magnitude to the IVW analyses and gave stronger 
evidence with an OR of 1.14 (95%CI:1.02-1.28;p=0.02) (Supplementary Table 1). The OR for 
advanced PCa per SD unit increase in IGFBP-3 was 1.16 (95%CI:0.87-1.55;p=0.19) from IVW 
analyses. The multivariable estimate was of similar magnitude to the IVW analyses, but gave stronger 
evidence with an OR of 1.22 (95%CI:1.07-1.40;p=0.004) (Supplementary Table 1).    
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Observational association between circulating 25(OH)D and IGFBP-3 in ProtecT  
Mean circulating IGFBP-3 levels were higher in the cases compared to the controls in ProtecT 
(4634.77ng/ml versus 4502.19ng/ml, p for difference=0.002). Mean season-adjusted circulating 
25(OH)D levels did not differ between cases and controls (22.75 ng/ml versus 22.71 ng/ml, 
respectively, p for difference=0.87). Mean season-adjusted 1,25(OH)2D levels did not differ between 
cases and controls (40.71pg/ml versus 42.06pg/ml, respectively, p for difference=0.12)  (Table 1). For 
cases and controls combined, circulating 25(OH)D and season-adjusted 25(OH)D were positively 
correlated with 1,25(OH)2D levels (r=0.24;p<0.001 and r=0.22;p<0.001, respectively) (Supplementary 
Table 2).  
 
For cases and controls combined, an SD unit increase (SD=7.8ng/ml) in circulating 25(OH)D was 
associated with a 0.09 SD (95%CI:0.05,0.13;p<0.001) increase in circulating IGFBP-3 levels.  A 0.09 
SD unit increase in IGFBP-3 is equivalent to 93.3ng/ml. There was no strong evidence for difference 
between cases and controls (Table 2). We found evidence that circulating 25(OH)D and IGFBP-3 are 
associated with potential confounding factors including age, BMI and diabetes status (Supplementary 
Table 3). After adjustment for confounders, the effect (beta: 0.09; 95% CI: 0.04, 0.14; p<0.001) was 
similar in magnitude to the unadjusted analysis.  When stratified by case-control status, the precision 
of the estimates was reduced due to smaller sample sizes (Table 2). We found little evidence for a 
non-linear effect of vitamin D on IGFBP-3 (p=0.43).  
 
For cases and controls combined, an SD unit increase in circulating 1,25(OH)2D was associated with a 
0.09 SD (95%CI:0.04,0.14;p=0.001) increase in IGFBP-3 (Table 2). We found evidence for 
association between 1,25(OH)2D and potential confounders including BMI, family history of PCa, 
smoking and diabetes status (Supplementary Table 3). After adjustment for potential confounders, 
the effect (beta: 0.09; 95%CI: 0.03, 0.15; p=0.003) was similar in magnitude to the unadjusted 
analysis. When stratified by case-control status, the precision of the estimates was reduced due to 
smaller sample sizes (Table 2).  
 
Validation of the instruments for circulating 25(OH)D in ProtecT  
A MR assumption is that there is a reliable association between the genetic instrument and the 
exposure48. We validated this using data from ProtecT in which 1,416 individuals had both genotype 
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data and 25(OH)D measured. In cases and controls combined, per unit increase in the allele score 
was associated with a 0.11 SD unit increase in 25(OH)D. There was no strong evidence for difference 
between cases and controls. For an individual with the maximum number of 25(OH)D increasing 
alleles (12), this corresponds to a 1.32 SD unit difference (on average) in 25(OH)D when compared to 
an individual with the minimum (0) number of 25(OH)D increasing alleles. This is higher in magnitude 
and is comparable to that of vitamin D supplementation which increases 25(OH)D by 0.45 SD units35. 
In cases and controls combined, the metabolism score was associated with increased 25(OH)D 
(p<0.001). For the metabolism score, there was no strong evidence for difference between cases and 
controls. In cases and controls combined, the synthesis score was found to be associated with 
increased 25(OH)D; however, the precision of the estimates was reduced when stratified by case-
control status due to reduced sample size (Supplementary Table 4).   
 
Using the allele score, each additional 25(OH)D-related allele was associated with a 0.05 pg/ml 
increase in 1,25(OH)2D in cases and controls combined. There was no strong evidence for difference 
between cases and controls. In cases and controls combined, the metabolism score was also found to 
be associated with increased 1,25(OH)2D (p=0.005); however, the precision of the estimates was 
reduced when stratified by case-control status due to reduced sample size (Supplementary Table 4). 
 
Another MR assumption is that the genetic instrument should not be associated with confounders 
(measured or unmeasured) of the exposure-outcome relationship48. There was little evidence that the 
allele, metabolism or synthesis score) were associated with potential confounders (Supplementary 
Table 5).   
 
Causal associations between 25(OH)D and IGFBP-3: one-sample MR in ProtecT   
The causal effect of 25(OH)D on IGFBP-3 was estimated using one-sample MR (Figure 2). Using the 
allele score as an instrument for 25(OH)D, for cases and controls combined, the instrumental variable 
(IV) estimate of the causal relationship between a one SD increase in 25(OH)D and IGFBP-3 for 
cases and controls combined was -0.32 SD units (95%CI:-0.64,-0.01;p=0.04). When stratified by case-
control status, the IV estimate for the controls was -0.10 (95%CI:-0.62,0.41;p=0.69) and the IV 
estimate for the cases was -0.30 (95%CI:-0.79,-0.02; p=0.04). Sensitivity analyses based on the use 
of individual SNPs, synthesis and metabolism score showed little evidence that 25(OH)D was causally 
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associated with IGFBP-3 (Table 3;Figure 3). The first-stage F-statistic using the allele score and 
metabolism score was 46.76 and 41.12, respectively. There was evidence of a departure of 
instrumental variable-derived estimates from those derived from observational analyses (Durbin-Wu-
Hausman test p=0.007) (Table 3).   
 
Causal associations between 25(OH)D and IGFBP-3: two-sample MR  
Using the six 25(OH)D-associated SNPs for the two-sample MR analysis, the IVW estimate between a 
one log-unit increase in 25(OH)D and IGFBP-3 was 0.11 SD units (95%CI:-0.10,0.31;p=0.32) (Figure 
3). In leave-one-out analyses, sequentially omitting each of the six 25(OH)D associated SNPs 
provided similar causal estimates to IVW analysis (Supplementary Table 6).  
 
Sensitivity analyses using SNPs involved in 25(OH)D synthesis found that the IVW estimate between 
a one log-unit increase in 25(OH)D and IGFBP-3 was 0.15  SD units (95%CI:-0.30,0.61;p=0.51). 
Using SNPs involved in 25(OH)D metabolism, the IVW estimate between a one log-unit increase in 
25(OH)D and IGFBP-3 was 0.07 SD units (95%CI:-0.17,0.31;p=0.59) (Figure 3). 
 
In the reverse direction, we investigated the causal effect of IGFBP-3 on 25(OH)D using the two-
sample MR. The IVW estimate between a one SD increase in IGFBP-3 and 25(OH)D was 0.01 log-
units (95%CI:-0.003,0.03;p=0.10) (Supplementary Table 7).  
 
Discussion 
This study supported results from previous studies that the IGF pathway is associated with increased 
odds of PCa and of advanced PCa - in particular IGFBP-34,5. Existing preclinical research has 
implicated 1,25(OH)2D in the regulation of IGFBP-3 expression and in this context we set out to 
assess the causal relationship between the closest modifiable proxy for this (25(OH)D) and IGFBP-3. 
Using data from ProtecT, this study found observational evidence that 25(OH)D and 1,25(OH)2D are 
associated with IGFBP-3 in the circulation. However, MR analyses using data from ProtecT were not 
suggestive of a causal effect for 25(OH)D. Using summary statistics from the new IGFBP-3 GWAS, 
two-sample MR analyses found little evidence of a causal relationship between circulating 25(OH)D 
and IGFBP-3.  
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The relationship of vitamin D and IGFBP-3 is complex due to the co-existing endocrine and 
autocrine/paracrine interactions6. At the autocrine/paracrine level, several preclinical studies have 
demonstrated that 1,25(OH)2D regulates IGFBP-3 expression6,7 and that the growth inhibitory effects 
of 1,25(OH)2D on PCa cells is altered by IGFBP-314-16. At the endocrine level, evidence from 
observational studies examining whether 25(OH)D or 1,25(OH)2D influence IGFBP-3 in the circulation 
have been conflicting, but inferences of causality are limited with observational studies due to effects 
of confounding and reverse causation17-20. Our MR results suggesting that 25(OH)D does not have a 
causal effect on IGFBP-3 levels in the circulation are in agreement with the results from a randomized 
phase II trial of men with localised PCa and high grade prostatic intraepithelial neoplasia which found 
that supplementation with the vitamin D analog,1-alpha-hydroxyvitamin D2, did not have an effect on 
circulating IGFBP-3 levels49. Another vitamin D supplementation trial conducted among women with 
high risk of breast cancer also found little evidence that circulating IGFBP-3 levels changed after 
supplementation with 25(OH)D50. This does not preclude that increasing the availability of 25(OH)D 
with supplementation may lead to increased production of 1,25(OH)2D within tissues that could then 
stimulate the local production of IGFBP-3 that is not detected in the circulation. 
 
Evidence from this study corroborates that the IGF pathway is a risk factor for PCa risk and 
progression3-5, but challenges assumptions about the possible route from supplement-derived 
precursor vitamin D, through IGFBP-3 to cancer. This work sits in the broader context of a prospective 
nested case-control study which found evidence for interactions between plasma 25(OH)D and 
plasma IGF-I/IGFBP-3 ratio with regard to colorectal cancer risk20. Another study of premenopausal 
women also reported that vitamin D supplementation was negatively associated with mammographic 
breast density, and that the association was stronger in those with high IGF-I and IGFBP-3 levels18.  
 
There could be several reasons why our MR findings differ from results from the observational studies. 
Firstly, the point estimates are close to the null for our 2 sample MR analyses. It is possible that the 
true effect of 25(OH)D on IGFBP-3 could be small and undetectable using a causal analysis 
framework. Secondly, the genetic instruments for 25(OH)D may not be acting as a true proxy for 
1,25(OH)2D. Our analyses using the allele and metabolism score found that each additional 25(OH)D-
related allele was associated with increased 1,25(OH)2D levels for controls and cases combined 
(Supplementary Table 4). However, the F-statistic for instrumental analyses using allele, metabolism 
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and synthesis scores was lower for 1,25(OH)2D compared to 25(OH)D (Table 3), indicating that they 
are weaker instruments for 1,25(OH)2D. Our observational analyses in ProtecT found that 1,25(OH)2D 
is associated with IGFBP-3 in the circulation; however, it is still unclear if a causal relationship exists 
between circulating 1,25(OH)2D and IGFBP-3. Thirdly, given that vitamin D activating enzymes are 
present in many tissues and could influence 1,25(OH)2D concentrations within tissues, including 
prostate tissues51,52, circulating 25(OH)D and 1,25(OH)2D may not reflect the true bioavailability of 
25(OH)D and 1,25(OH)2D within tissues. Therefore, the endocrine relationship between 25(OH)D and 
IGFBP-3 may not be reflective of the autocrine/paracrine relationship.  
 
Our study has several limitations. The SNPs associated with IGFBP-3 have been shown to be 
associated with more than one part of the IGF pathway. Although the multivariable MR method 
enables the determination of the causal effect of IGFBP-3 on PCa independent of IGF-I, we cannot 
rule out associations with other members of the IGF pathway5. As only a small number of SNPs were 
included in our MR analyses, methods to test for pleiotropy such as the MR-Egger43, weighted 
median44 and mode45 method were not conducted as these lack power with small number of SNPs. As 
the SNPs associated with 25(OH)D only explained a small proportion of the variability in circulating 
25(OH)D, large sample sizes are required to detect expected influences on IGFBP-3 levels and to be 
able to provide precise estimates for this effect. Although our point estimates are close to the null for 
the two-sample MR analyses, we cannot rule out the possibility that 25(OH)D may have small effects 
on IGFBP-3. Lastly, our study population was limited to Europeans. Although population homogeneity 
eliminates population admixture as a potential confounder in our analyses, as 25(OH)D levels vary 
with sun exposure and skin colour, the findings drawn from this study might not be applicable to other 
ethnic groups or individuals in different geographical locations.  
 
Conclusions   
This study confirmed results from previous studies that members of the IGF pathway, in particular 
IGFBP-3, has a causal effect on PCa and advanced PCa. Observationally, there is evidence that 
circulating 25(OH)D is positively associated with circulating IGFBP-3, but MR analyses indicated these 
findings were unlikely to be causal. Findings here are limited by the nature of instrumentation of both 
25(OH)D and IGFBP-3 and the utility of circulating measures, but are important as they suggest that 
circulating 25(OH)D are unlikely to be causally related to circulating IGFBP-3, although vitamin D 
  14 
supplementation could affect local tissue levels.  
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Table 1. Baseline characteristics of participants in the ProtecT study 
Continuous variables Controls (N=1449) Cases (N=1446) 
 N Mean (SD or IQR) N Mean (SD or IQR) 
IGFBP-3 (ng/ml) 1071 4502.19 (1026.06) 1366 4634.77 (1041.58) 
25(OH)D (ng/ml) 1449 22.93 (8.36) 1446 23.05 (8.71) 
season-adjusted 25(OH)D (ng/ml) 1449 22.73 (7.86) 1446 22.75 (7.97) 
1,25(OH)2D (pg/ml) 872 42.03 (18.05) 925 40.85 (18.42) 
season-adjusted 1,25(OH)2D (pg/ml) 872 42.06 (18.02) 925 40.71 (18.24) 
Age (years) 1449 62.38 (5.02) 1446 62.59 (5.00) 
BMI (kg/m2) 1067 27.35 (3.94) 1177 27.17 (3.62) 
PSA (ng/ml) 1449 1.39 (1.27) 1446 9.39 (26.46) 
IGF-I (ng/ml) 1082 165.46 (54.49) 1405 157.69 (52.61) 
IGF-II (ng/ml) 1072 759.93 (270.14) 1366 851.38 (314.96) 
IGFBP-2 (ng/ml) 1069 694.08 (410.05) 1404 716.26 (407.67) 
Categorical variables N % N % 
aSocial class     
Managerial and professional 608 41.96 594 41.08 
Intermediate 235 16.22 219 15.15 
Working 586 40.44 587 40.59 
Missing 20 1.38 46 3.18 
bFamily history of BPH     
No 62 4.28 54 3.73 
Yes 1272 87.78 1297 89.70 
Possible 84 5.80 63 4.36 
Not known/Not given 31 2.14 32 2.21 
cFamily history of PCa     
No 1234 85.16 1182 81.74 
Yes 75 5.18 107 7.40 
Missing 140 9.66 157 10.86 
dSmoking     
Never 300 20.70 438 30.29 
Ever 705 48.65 768 53.11 
Missing 364 25.12 240 16.60 
Ethnicity     
White 1428 98.55 1414 97.79 
Others 15 1.04 17 1.18 
Missing 6 0.41 15 1.04 
eDiabetes     
Yes 936 64.60 1045 72.27 
No 86 5.94 66 4.56 
Missing 427 29.47 335 23.17 
Study centre     
Sheffield 216 14.91 213 14.73 
Newcastle 193 13.32 193 13.35 
Bristol 132 9.11 130 8.99 
Cardiff 148 10.21 147 10.17 
Edinburgh 129 8.90 130 8.99 
Birmingham 32 2.21 33 2.28 
Leicester 265 18.29 264 18.26 
Cambridge 163 11.25 162 11.20 
Leeds 171 11.80 174 12.03 
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Table 1. Cont. 
 
 
 
 
 
 
 
 
 
 
IGFBP-3, insulin-like growth factor binding protein-3; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 
IGFBP-2, insulin-like growth factor binding protein-2; IGF-1, insulin-like growth factor 1; IGF-2, insulin-like growth factor 2; N, 
sample size; SD, standard deviation; IQR, inter quartile range; BPH, benign prostatic hyperplasia; PCa, PCa; BMI, body mass 
index; PSA, prostate specific antigen;  
Normally distributed variables are presented as the means ± standard deviation, non-normally distributed variables are 
presented as medians (interquartile range)(*). 
aThree-class social categorization from Rose and O'Reilly (1998).  
bFamily history of benign prostatic hyperplasia is categorized as ‘yes’, ‘no’, ‘possible’ and ‘unknown’.
 
cFamily history of PCa is coded yes if father or brother were diagnosed with PCa.  
dSmoking status was dichotomized and defined as ‘ever’ (ex-smoker or current smoker) versus ‘never smokers’. 
eDiabetes status as diagnosed by a doctor and was categorized as “yes” or “no”.  
fWeekly exercise calculated from the frequency of participation in exercise of mild, moderate and strenuous intensity. Weekly 
exercise was categorized as ‘None’, ‘1-2 times’, ‘3-4 times’, ‘>5 times’. 
 
All men included in the table have both 25-hydroxyvitamin D (25(OH)D) and IGFBP-3 measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Categorical variables N % N % 
fPhysical activity (per week)     
None 481 33.20 550 38.04 
1-2 times 355 24.50 367 25.38 
3-4 times 159 10.97 184 12.72 
5+ times 64 4.42 78 5.39 
Missing 390 26.92 267 18.46 
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Table 2. Association between circulating season-adjusted 25(OH)D (ng/ml) and 1,25(OH)2D (ng/ml) with IGFBP-3 for cases and controls in the ProtecT study.  
 
 25(OH)D 1,25(OH)2D 
 N aSD unit 
change in 
IGFBP-3 
(ng/ml) per 
SD increase 
in 25(OH)D  
(95% CI) 
p value 
 
N bSD unit 
change in 
IGFBP-3 
(ng/ml) per 
SD increase 
in 25(OH)D  
(95% CI) 
p value 
 
N aSD unit 
change in 
IGFBP-3 
(ng/ml) per 
SD increase 
in 1,25(OH)2D 
(95% CI) 
p value 
 
N bSD unit 
change in 
IGFBP-3 
(ng/ml) per SD 
increase in   
1,25(OH)2D
 
(95% CI) 
p value 
 
Cases and 
controls 
2437 0.09  
(0.05, 0.13) 
<0.001 1559 0.09 
(0.04, 0.14) 
<0.001 1428 0.09 
(0.04, 0.14) 
0.001 955 0.09 
(0.03, 0.15) 
0.003 
Controls 
only 
1071 0.07  
(0.01, 0.14) 
0.02 666 0.07 
(-0.001, 0.15) 
0.05 562 0.10 
(0.03, 0.20) 
0.01 354 0.12 
(0.03, 0.22) 
0.01 
Cases only 1366 0.11 
(0.05, 0.16) 
<0.001 893 0.10 
(0.04, 0.16) 
0.002 866 0.08 
(0.01, 0.15) 
0.02 601 0.07 
(-0.01, 0.15) 
0.10 
N, sample size; SD, standard deviation; IGFBP-3, insulin-like growth factor binding protein 3; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25 dihydroxyvitamin D; 95% CI, 95% confidence interval 
aAdjusted for case-control status  
bAdjusted for age, centre, case-control status, PSA levels, smoking status, social class, BMI, ethnicity, family history of PCa, history of benign hyperplasia, physical activity and diabetes status.  
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Table 3. Beta estimates of SD unit change in IGFBP-3 per SD unit increase in 25(OH)D and 1,25(OH)2D based on one-sample Mendelian randomization analysis in the ProtecT study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25(OH)D 1,25(OH)2D 
Instruments N aBeta (95% CI) p value  
 
bF-statistic cp value  
(DWH)  
N aBeta (95% CI) p 
value  
 
bF-statistic cp value  
(DWH)  
rs3755967 (overall) 1207 -0.30 (-0.63, 0.04) 0.08 39.04 0.02 1195 -5.30 (-1.24, 0.18) 0.14 11.06 0.03 
rs3755967 (controls) 487 -0.23 (-0.77, 0.31) 0.40 14.67 0.32 485 -0.35 (-1.24, 0.53) 0.44 6.35 0.23 
rs3755967 (cases) 720 -0.31 (-0.72, 0.11) 0.15 24.85 0.04 710 -0.59 (-1.63, 0.44) 0.26 5.30 0.10 
           
rs12785878 (overall) 1134 0.30 (-1.47, 2.07) 0.74 1.27 0.80 1124 0.44 (-1.32, 2.20) 0.62 1.39 0.71 
rs12785878 (controls) 460 1.26 (-9.32, 11.83) 0.82 0.08 0.72 458 0.32 (-0.95, 1.60) 0.62 2.52 0.76 
rs12785878 (cases) 674 0.23 (-1.33, 1.79) 0.77 1.58 0.86 666 1.64 (-11.47, 14.74) 0.81 0.07 0.68 
           
rs10741657 (overall) 1207 0.03 (-0.67, 0.73) 0.93 7.59 0.91 1195 0.15 (-1.24, 1.55) 0.83 1.99 0.97 
rs10741657 (controls) 487 1.12 (-0.42, 2.65) 0.15 3.57 0.04 485 2.14 (-2.35, 6.63) 0.35 0.97 0.05 
rs10741657 (cases) 720 -0.76 (-2.01, 0.49) 0.23 4.10 0.08 710 -1.36 (-4.75, 2.04) 0.43 1.05 0.13 
           
rs17216707 (overall) 1207 -0.36 (-1.69, 0.98) 0.60 2.48 0.50 1195 -1.69 (-11.40, 8.01) 0.73 0.18 0.45 
rs17216707 (controls) 487 -0.42 (-1.47, 0.63) 0.43 4.22 0.35 485 27.35 (-1533.39, 1588.10) 0.97 0.001 0.36 
rs17216707 (cases) 720 -0.40 (-7.84, 7.03) 0.92 0.08 0.88 710 -0.45 (-4.48, 3.58) 0.83 0.31 0.75 
           
rs10745742 (overall) 1207 -2.53 (-17.64, 12.59) 0.74 0.13 0.35 1195 -6.92 (-103.79, 89.94) 0.89 0.02 0.31 
rs10745742 (controls) 487 0.04 (-4.43, 4.50) 1.00 0.19 1.00 485 -0.10 (-3.80, 3.59) 0.95 0.31 0.90 
rs10745742 (cases) 720 -7.13 (-105.48, 91.21) 0.89 0.02 0.28 710 -1.73 (-7.81, 4.35) 0.58 0.45 0.21 
           
rs8018720 (overall) 1207 -1.35 (-3.91, 1.21) 0.30 1.76 0.06 1195 4.48 (-16.65, 25.62) 0.68 0.17 0.07 
rs8018720 (controls) 487 0.77 (-0.64, 2.17) 0.29 3.01 0.21 485 2.46 (-6.73, 11.66) 0.60 0.29 0.22 
rs8018720 (cases) 720 -0.43 (-1.14, 0.29) 0.24 9.24 0.11      
  3 
Table 3. Cont.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N, sample size; Beta, regression coefficient; 95% CI, 95% confidence interval; DWH, Durbin-Wu-Hausman; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25 dihydroxyvitamin D.  
aBeta refers to the SD unit change in IGFBP-3 levels per 1 SD unit increase in 25(OH)D or 1,25(OH)2D 
bF statistic indicates how much of the variability in 25(OH)D is explained by each SNP or allele score (i.e., the strength of each SNP as an instrument for vitamin D levels. F>10 indicates a strong 
instrument.  
cp value(DWH) is the p value for a test (the Durbin form of the Durbin-Wu Hausman test) for the difference between the estimates from linear regression (without additional adjustment) and instrumental 
variable analysis.  
dAllele score: rs8018720, rs10745742, rs10741657, rs12785878, rs3755967 and rs17216707 
eSynthesis score: rs12785878 and rs10741657 
fMetabolism score: rs3755967 and rs1721
 25(OH)D 1,25(OH)2D 
Instruments N aBeta (95% CI) p value  
 
bF-statistic cp value  
(DWH)  
N aBeta (95% CI) p value  
 
bF-statistic cp value  
(DWH)  
dAllele score (overall) 1134 -0.32 (-0.64, -0.01) 0.04 46.76 0.007 1124 -0.61 (-1.33, 0.11) 0.10 11.72 0.01 
dAllele score (controls) 460 -0.10 (-0.62, 0.41) 0.69 15.01 0.59 458 -0.15 (-0.99, 0.68) 0.72 6.20 0.49 
dAllele score (cases) 674 -0.40 (-0.79, -0.02) 0.04 32.71 0.004 666 -0.87 (-2.01, 0.26) 0.13 5.96 0.02 
           
eSynthesis score 
(overall) 
1134 0.03 (-0.69, 0.76) 0.93 7.29 0.92 1124 0.15 (-1.06, 1.37) 0.81 2.66 0.96 
eSynthesis score 
(controls) 
460 0.97 (-0.74, 2.69) 0.27  2.44 0.14 458 0.97 (-0.59, 2.52) 0.22 2.76 2.77 
eSynthesis score 
(cases) 
674 -0.42 (-1.40, 0.56) 0.40 4.99 0.24 666 -0.98 (4.59, 2.64) 0.60 0.65 0.38 
           
fMetabolism score 
(overall) 
1207 -0.30 (-0.63, 0.03) 0.07 41.12 0.02 1195 -0.56 (-1.29, 0.16) 0.13 10.94 0.02 
fMetabolism score 
(controls) 
487 -0.25 (-0.74, 0.23) 0.31 18.14 0.23 485 -0.45 (-1.40, 0.50) 0.35 5.94 0.17 
fMetabolism score 
(cases) 
720 -0.31 (-0.74, 0.12) 0.16 23.50 0.05 710 -0.58 (-1.60, 0.43) 0.26 5.46 0.10 
  1 
 
  2 
 
  3 
 
 
 
  4 
 
 
 
  5 
 
 
 
 
Supplementary Table 1. Association between IGFBP-3 and prostate cancer risk and risk of advanced prostate cancer in the PRACTICAL Consortium. 
 
MR, Mendelian Randomization; N, sample size; CI, confidence interval; IVW, 
inverse variance weighted; ML: maximum likelihood 
aAssociations are per 1 SD unit increase in IGFBP-3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRACTICAL Consortium Controls 
(N) 
Cases 
(N) 
aOR (95% CI) p value 
Risk  
(Two-sample MR) 
27,904 44,825  IVW: 1.12 (0.91, 1.36) 
 
ML: 1.12 (1.05, 1.19) 
IVW: 0.18 
 
ML: <0.001 
 
 
Risk  
(Multivariable MR)  
27,904 44,825 1.14 (1.02, 1.28) 0.02 
Advanced stage  
(Two-sample MR) 
27,235 6,263 IVW: 1.16 (0.87, 1.55) 
 
ML: 1.17 (1.04, 1.31) 
IVW: 0.19 
 
ML:0.006 
 
Advanced stage  
(Multivariable MR) 
27,235 6,263 1.22 (1.07, 1.40) 0.004 
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Supplementary Table 2. Correlation between 25(OH)D and 1,25 (OH)2D for cases and controls in ProtecT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; R, Pearson correlation; N, sample size 
 
 
 
 
 
 
 
 
 
  1,25(OH)D 
 N R p value 
25(OH)D (overall) 1797 0.24 <0.001 
25(OH)D (controls) 872 0.20 <0.001 
25(OH)D (cases) 925 0.28 <0.001 
  Season-adjusted 1,25(OH)D 
 N R p value 
Season-adjusted 25(OH)D  
(overall) 
1797 0.22 <0.001 
Season-adjusted 25(OH)D 
(controls) 
872 0.18 <0.001 
Season-adjusted 25(OH)D 
(cases) 
925 0.25 <0.001 
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Supplementary Table 3. Association between circulating 
25(OH)D and IGFBP-3 levels with potential confounding 
factors for cases and controls in the ProtecT study. 
 
 
25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25 
dihydroxyvitamin D; IGFBP-3, insulin-like growth factor 
binding protein-3; N, sample size; Beta, regression coefficient; 
95% CI, 95% confidence interval; PSA levels, prostate specific 
antigen levels; BMI, body mass index; BPH, benign prostatic 
hyperplasia;  PCa, Prostate cancer 
aBeta refers to unit change in 25(OH)D (ng/ml), 1,25(OH)2D 
(ng/ml) or IGFBP-3 (ng/ml) levels per unit increase in 
confounders. Calculated using unadjusted linear regression 
bSmoking status was dichotomized and defined as ‘ever’ (ex-
smoker or current smoker) versus ‘never smokers’. 
cThree-class social categorization from Rose and O'Reilly 
(1998).   
dWeekly exercise calculated from the frequency of 
participation in exercise of mild, moderate and strenuous 
intensity. Weekly exercise was categorized as ‘None’, ‘1-2 
times’, ‘3-4 times’, ‘>5 times’. 
 
eFamily history of benign prostatic hyperplasia is categorized 
as ‘yes’, ‘no’, ‘possible’ and ‘unknown’. 
fFamily history of prostate cancer is coded yes if father or 
brother were diagnosed with prostate cancer.  
gDiabetes status as diagnosed by a doctor and was 
categorized as “yes” or “no”. 
 
 
 
 
 
 
 
 
 
Potential 
Confounding 
factors 
IGFBP-3 (ng/ml) 25(OH)D (ng/ml) 1,25(OH)2D (pg/ml) 
 N aBeta 
(95% CI) 
 
p value 
 
N aBeta 
(95% CI) 
 
p value 
 
N aBeta 
(95% CI) 
 
p value 
 
Age (years) 2437 -37.08 
(-45.20, -28.97) 
<0.001 2895 0.07 
(0.01, 0.13) 
0.01 1797 -0.04 
(-0.21, 0.12) 
 
0.62 
Centre 2437 10.18 
(-4.94, 25.30) 
0.19 2895 0.06 
(-0.05, 0.16) 
0.28 1797 -0.005 
(-0.29, 0.28) 
 
0.97 
PSA levels 
(ng/ml) 
2437 -1.61 
(-3.60, 0.37) 
0.11 2895 -0.02 
(-0.03, -0.0001) 
0.05 1797 0.006 
(-0.03, 0.04) 
0.74 
BMI (kg/m2) 1904 11.19 
(-1.42, 23.81) 
0.08 2244 -0.20 
(-0.28, -0.11) 
<0.001 1438 -0.57 
(-0.81, -0.32) 
<0.001 
bSmoking status 1941 -75.64 
(-171.68, 20.41) 
0.12 2291 -0.89 
(-1.55, -0.22) 
0.01 1471 -2.50 
(-4.46, -0.54) 
0.01 
cSocial Class 2382 -35.79 
(-81.37, 9.78) 
0.12 2829 -0.14 
(-0.45, 0.18) 
0.40 1770 -0.39 
(-1.31, 0.54) 
0.42 
dPhysical 
activity 
1896 2.33 
(-48.47, 53.14) 
0.93 
 
2238 1.03 
(0.68, 1.38) 
<0.001 1439 1.00 
(-0.02, 2.03) 
 
0.06 
eHistory of BPH 2437 32.50 
(-65.85, 130.86) 
0.52 2895 -0.39 
(-1.07, 0.30) 
0.27 1797 -0.52 
(-2.53, 1.49) 
 
0.61 
fFamily history 
of PCa 
2184 -104.02 
(-270.53, 62.49) 
0.22 2598 -1.09 
(-2.27, 0.09) 
0.07 1618 -5.10 
(-8.60, -1.61) 
 
0.004 
Ethnicity 2419 -31.69 
(-123.39, 60.02) 
0.50 2874 -0.98 
(-1.55, -0.41) 
0.001 1787 -0.55 
(-2.21, 1.12) 
 
0.52 
gDiabetes 1806 -520.11  
(-706.33, -333.90) 
<0.001 2133 -1.67 
(-2.96, -0.39) 
0.01 1371 -8.40 
(-12.03, -4.78) 
 
<0.001 
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     25(OH)D (SD units) 1,25(OH)2D (SD units) 
Genotype Gene Chr Effect/ 
Other 
allele 
 N aBeta 
(95%CI) 
p value 
 
N aBeta 
(95%CI) 
p 
value 
 
rs3755967 GC 4 C/T Overall 1501 0.29  
(0.21, 0.37)  
<0.001 1487 0.14  
(0.06, 0.22) 
0.001 
    Controls 739 0.30  
(0.18, 0.41) 
<0.001 737 0.14 
(0.03, 0.25) 
0.02 
    Cases 762 0.29  
(0.18, 0.40) 
<0.001 750 0.14 
(0.03, 0.25) 
0.01 
rs12785878 DHCR7 11 T/G Overall 1416 0.04  
(-0.05, 0.14) 
0.37 1404 0.06 
(-0.02, 0.16) 
0.20 
    Controls 702 0.02  
(-0.13, 0.16) 
0.82 700 0.12 
(-0.02, 0.25) 
0.09 
    Cases 714 0.07  
(-0.06, 0.20) 
0.29 704 0.01  
(-0.12, 0.14) 
0.90 
rs10741657 CYP2R1 11 A/G Overall 1501 0.12  
(0.05, 0.19) 
0.002 1487 0.03 
(-0.04, 0.10) 
0.42 
    Controls 739 0.11  
(0.003, 0.22) 
0.04 737 -0.01 
(-0.11, 0.10) 
0.92 
    Cases 762 0.13  
(0.03, 0.23) 
0.01 750 0.06 
(-0.04, 0.16) 
0.22 
rs17216707 CYP24A1 20 T/C Overall 1501 0.08  
(-0.02, 0.17) 
0.11 1487 0.02 
(-0.08, 0.11) 
0.74 
    Controls 739 0.12  
(-0.01, 0.26) 
0.07 737 0.002 
(-0.13, 0.13) 
0.98 
    Cases 762 0.03  
(-0.11, 0.17) 
0.66 750 0.03 
(-0.10, 0.16) 
0.65 
rs10745742 AMDHD1 12 T/C Overall 1501 0.12  
(0.05, 0.19) 
0.002 1487 0.03 
(-0.04, 0.10) 
0.42 
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Supplementary Table 4. Association between vitamin D genotypes and 
circulating 25(OH)D and 1,25(OH)2D for cases and controls in the ProtecT 
study. 
 
 
Chr, Chromosome; 25(OH)D, 25-hydroxyvitamin D, 1,25(OH)2D, 1,25-
dihydroxyvitamin D; N, sample size; Beta, regression coefficient; 95% CI, 
95% confidence interval.  
aBeta refers to change in 25(OH)D (SD units) levels per each additional 
copy of the effect allele. Calculated using linear regression with adjustment for 
case-control status for overall analyses. An SD unit of 25(OH)D is 7.8 
ng/ml.  
bAllele score: rs8018720, rs10745742, rs10741657, rs12785878, 
rs3755967 and rs17216707 
cSynthesis score: rs12785878 and rs10741657 
dMetabolism score: (rs3755967 and rs17216707) 
 
 
 
 
 
 
 
Supplementary Table 5. Association between vitamin D genotypes and potential confounders for cases and controls in the ProtecT study.  
Potential Confounders 
with Genotypes or Allele 
Score 
N 
 
aBeta/bOR 
(95% CI) 
p value 
 
aAge (years)    
rs3755967 1501 -0.06 (-0.45, 0.34) 0.77 
rs12785878 1416 0.22 (-0.25, 0.69) 0.36 
rs10741657 1501 -0.29 (-0.65, 0.07) 0.12 
rs17216707 1501 0.12 (-0.34, 0.58) 0.61 
rs10745742 1501 0.03 (-0.35, 0.41) 0.88 
rs8018720 1501 -0.01 (-0.47, 0.45) 0.98 
cAllele Score 1416 -0.09 (-0.26, 0.10) 0.37 
dSynthesis score 1416 -0.10 (-0.39, 0.19) 0.51 
eMetabolism score 1501 0.02 (-0.28, 0.31) 0.92 
    Controls 739 0.11  
(0.003, 0.22) 
0.04 737 -0.01 
(-0.11, 0.10) 
0.92 
    Cases 762 0.13  
(0.03, 0.23) 
0.01 750 0.06 
(-0.04, 0.16) 
0.22 
rs8018720 SEC23A 14 G/C Overall 1501 0.05  
(-0.04, 0.15) 
0.28 1487 0.02 
(-0.07, 0.12) 
0.60 
    Controls 739 -0.11  
(-0.25, 0.02) 
0.11 737 0.03 
(-0.10, 0.17) 
0.63 
    Cases 762 0.20  
(0.08, 0.33) 
0.002 750 0.02 
(-0.11, 0.14) 
0.80 
bAllele score    Overall 1416 0.11  
(0.08, 0.15) 
<0.001 1404 0.05 
(0.01, 0.08) 
0.01 
bAllele score    Controls 702 0.10  
(0.02, 0.15) 
<0.001 700 0.04 
(-0.01, 0.09) 
0.12 
 
bAllele score    Cases 714 0.13  
(0.08, 0.18) 
<0.001 704 0.06 
(0.01, 0.10) 
0.02 
cSynthesis score    Overall 1416 0.09  
(0.03, 0.15) 
0.003 1404 0.04 
(-0.02, 0.09) 
0.22 
cSynthesis score    Controls 702 0.08  
(-0.01, 0.17)  
0.09 700 0.04 
(-0.05, 0.12) 
0.41 
cSynthesis score    Cases 714 0.10  
(0.02, 0.18) 
0.01 704 0.04 
(-0.03, 0.11) 
0.36 
dMetabolism score    Overall 1416 0.20  
(0.14, 0.26) 
<0.001 1487 0.09 
(0.03, 0.14) 
0.005 
dMetabolism score    Controls 702 0.23  
(0.14, 0.31) 
<0.001 737 0.08 
(-0.004, 
0.17) 
0.06 
dMetabolism score    Cases 714 0.18  
0.09, 0.26) 
<0.001 750 0.09 
(0.01, 0.17) 
0.03 
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Potential Confounders 
with Genotypes or Allele 
Score 
N 
 
aBeta/bOR 
(95% CI) 
p value 
 
aCenter    
rs3755967 1501 -0.06 (-0.29, 0.17) 0.61 
rs12785878 1416 -0.13 (-0.40, 0.14) 0.35 
rs10741657 1501 0.14 (-0.07, 0.35) 0.18 
rs17216707 1501 -0.27 (-0.54, -0.003) 0.05 
rs10745742 1501 0.14 (-0.08, 0.36) 0.20 
rs8018720 1501 0.002 (-0.26, 0.27) 0.99 
cAllele Score 1416 -0.001 (-0.10, 0.10) 0.99 
dSynthesis score 1416 0.06 (-0.11, 0.23) 0.49 
eMetabolism score 1501 -0.15 (-0.32, 0.03) 0.10 
aPSA levels (ng/ml)    
rs3755967 1501 -0.06 (-0.15, 0.03) 0.19 
rs12785878 1416 -0.08 (-0.19, 0.02) 0.13 
rs10741657 1501 0.002 (-0.08, 0.08) 0.97 
rs17216707 1501 0.09 (-0.02, 0.19) 0.10 
rs10745742 1501 -0.08 (-0.16, 0.01) 0.07 
rs8018720 1501 0.03 (-0.07, 0.13) 0.56 
cAllele Score 1416 -0.02 (-0.06, 0.02) 0.28 
dSynthesis score 1416 -0.02 (-0.09, 0.04) 0.48 
eMetabolism score 1501 
 
 
0.002 (-0.06, 0.07) 0.94 
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Supplementary Table 5 Cont.  
Potential Confounders with 
Genotypes or Allele Score 
N 
 
Betaa/ORb (95% CI) p value 
 
aBMI (kg/m2)    
rs3755967 1196 0.13 (-0.20, 0.45) 0.45 
rs12785878 1130 0.15 (-0.24, 0.54) 0.45 
rs10741657 1196 -0.17 (-0.46, 0.13) 0.27 
rs17216707 1196 0.003 (-0.38, 0.38) 0.99 
rs10745742 1196 0.02 (-0.29, 0.33) 0.89 
rs8018720 1196 -0.03 (-0.41, 0.34) 0.86 
cAllele Score 1130 0.02 (-0.13, 0.16) 0.81 
dSynthesis score 1130 -0.05 (-0.29, 0.19) 0.69 
eMetabolism score 1196  0.07 (-0.17, 0.31) 0.56 
bSmoking status    
rs3755967 1226 1.03 (0.86, 1.23) 0.77 
rs12785878 1157 1.08 (0.87, 1.34) 0.47 
rs10741657 1226 1.12 (0.95, 1.32) 0.17 
rs17216707 1226 0.99 (0.80, 1.23) 0.95 
rs10745742 1226 1.12 (0.94, 1.33) 0.20 
rs8018720 1226 1.02 (0.83, 1.26) 0.85 
cAllele Score 1157 1.06 (0.98, 1.15) 0.16 
dSynthesis score 1157 1.07 (0.94, 1.22) 0.29 
eMetabolism score 1226 1.01 (0.89, 1.16) 0.86 
aSocial class    
rs3755967 1476 -0.02 (-0.09, 0.05) 0.57 
rs12785878 1396 0.008 (-0.08, 0.09) 0.85 
rs10741657 1476 0.02 (-0.05, 0.08) 0.62 
rs17216707 1476 0.08 (-0.007, 0.16) 0.07 
rs10745742 1476 -0.03 (-0.10, 0.03) 0.33 
rs8018720 1476 -0.03 (-0.12, 0.05) 0.46 
cAllele Score 1396 0.003 (-0.03, 0.04) 0.84 
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dSynthesis score 1396 0.02 (-0.03, 0.07) 0.51 
eMetabolism score 1476 0.02 (-0.03, 0.07) 0.47 
aPhysical activity    
rs3755967 1196 -0.04 (-0.12, 0.04) 0.29 
rs12785878 1128 -0.03 (-0.13, 0.06) 0.53 
rs10741657 1196 -0.002 (-0.07, 0.07) 0.97 
rs17216707 1196 -0.06 (-0.16, 0.03) 0.19 
rs10745742 1196 -0.03 (-0.10, 0.05) 0.48 
rs8018720 1196 0.008 (-0.09, 0.10) 0.86 
cAllele Score 1128 -0.02 (-0.06, 0.01) 0.20 
dSynthesis score 1128 -0.009 (-0.07, 0.05) 0.76 
eMetabolism score 1196  -0.05 (-0.11, 0.01) 0.10 
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Supplementary Table 5 Cont. 
 
Potential Confounders with 
Genotypes or Allele Score 
N 
 
Betaa/ORb (95% CI) p value 
 
aHistory of BPH    
rs3755967 1501 -0.009 (-0.04, 0.03) 0.62 
rs12785878 1416 0.002 (-0.04, 0.04) 0.94 
rs10741657 1501 0.01 (-0.02, 0.04) 0.41 
rs17216707 1501 -0.02 (-0.06, 0.02) 0.39 
rs10745742 1501  0.01 (-0.02, 0.04) 0.49 
rs8018720 1501 -0.002 (-0.04, 0.04) 0.89 
cAllele Score 1416 0.0004 (-0.01, 0.02) 0.96 
dSynthesis score 1416 0.01 (-0.02, 0.03) 0.44 
eMetabolism score 1501 -0.01 (-0.04, 0.01) 0.35 
bFamily history of PCa    
rs3755967 1350 0.94 (0.69, 1.29) 0.72 
rs12785878 1277 0.90 (0.62, 1.30) 0.58 
rs10741657 1350 1.15 (0.86, 1.53) 0.35 
rs17216707 1350 0.81 (0.57, 1.15) 0.23 
rs10745742 1350 0.70 (0.51, 0.96) 0.03 
rs8018720 1350 0.98 (0.68, 1.42) 0.92 
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N, sample size; Beta, regression coefficient; OR, odds ratio; 95% CI, 95% confidence interval; PSA levels, prostate specific antigen levels; BMI, body mass index; BPH, benign prostatic hyperplasia; PCa, Prostate 
cAllele Score 1277 0.90 (0.78, 1.03) 0.13 
dSynthesis score 1277 1.01 (0.80, 1.27) 0.93 
eMetabolism score 1350 0.88 (0.70, 1.11) 0.30 
bDiabetes    
rs3755967 1141 1.00 (0.71, 1.40) 1.00 
rs12785878 1074 1.05 (0.70, 1.57) 0.81 
rs10741657 1141 1.05 (0.78, 1.43) 0.73 
rs17216707 1141 0.90 (0.61, 1.32) 0.58 
rs10745742 1141 1.25 (0.91, 1.72) 0.16 
rs8018720 1141 1.47 (1.02, 2.11) 0.04 
cAllele Score 1074 1.14 (0.98, 1.32) 0.09 
dSynthesis score 1074 1.10 (0.86, 1.40) 0.45 
eMetabolism score 1141 0.96 (0.74, 1.23) 0.72 
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cancer.  
aPer-allele effects were obtained by linear regression for continuous variables. 
bPer-allele effects were obtained by logistic regression for binary variables.  
d Allele score: rs8018720, rs10745742, rs10741657, rs12785878, rs3755967 and rs17216707. 
eSynthesis score: rs12785878 and rs10741657. 
f Metabolism score: rs3755967 and rs17216707. 
 
 
 
 
 
 
Supplementary Table 6. Leave one out analyses repeated for each possible combination of 25-hydroxyvitamin D genetic instruments   
 
Instruments Beta (95% CI) p 
Six 25(OH)D associated SNPs 
excluding rs10741657 
0.11 
(-0.11, 0.33) 
0.34 
Six 25(OH)D associated SNPs 
excluding rs10745742 
0.11  
(-0.11, 0.32) 
0.32 
Six 25(OH)D associated SNPs 
excluding rs12785878 
0.09  
(-0.13, 0.31) 
0.41 
Six 25(OH)D associated SNPs 
excluding rs17216707 
0.11  
(-0.10, 0.33) 
0.29 
Six 25(OH)D associated SNPs 
excluding rs3755967 
0.17  
(-0.20, 0.55) 
0.37 
Six 25(OH)D associated SNPs 
excluding rs8018720 
0.09  
(-0.12, 0.30) 
0.42 
Six 25(OH)D associated SNPs 
excluding rs10741657 
0.11  
(-0.10, 0.31) 
0.32 
25(OH)D, 25-hydroxyvitamin D; SNP, single nucleotide polymorphisms; CI, confidence interval; p, p-value.  
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Supplementary Table 7. Causal effect of IGFBP-3 on 25(OH)D using two sample MR analysis.  
 
Instruments Beta 
(95% CI) 
p-value 
rs1065656 0.01 (-0.03, 0.05) 0.57 
rs11977526 0.004 (-0.01, 0.02) 0.62 
rs4234798 0.05 (0.01, 0.09) 0.03 
rs700753 0.03 (0.01, 0.004) 0.02 
Overall (IVW) 0.01 (-0.003, 0.03) 0.10 
25(OH)D, 25-hydroxyvitamin D; SNP, single nucleotide polymorphisms; CI, confidence interval; IVW, inverse variance weighted 
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Supplementary Methods and Tables 
Study populations and data sources for observational and MR analyses 
ProtecT study 
Individual level analyses were based within the ProtecT trial (ISRCTN20141297), a large population-based cohort of approximately 80,000 men aged 50-69 years from across 
the UK who underwent PSA testing for prostate cancer, within which are nested case-control studies (1, 2). All men without evidence of prostate cancer (PSA test <3ng/mL, 
or men with PSA >3ng/mL but had at least one negative diagnostic biopsy) were eligible for selection as controls. Controls were randomly selected from the same stratum (5-
year age band and GP/family practice) as the cases who had provided a non-fasted blood sample at the prostate check clinic. Circulating concentrations of IGFBP-3 were 
measured using an in-house radioimmunoassay from blood serum. The intra-class correlations (ICC) for within-assay variability and between-assay variability for IGFBP-3 
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were 0.88 and 0.71, respectively. Circulating 25(OH)D2 and 25(OH)D3 in blood plasma (collected at diagnosis) were measured using tandem mass spectrometry. Circulating 
concentrations of 25(OH)D2 and 25(OH)D3 were measured in nanograms per millilitre (ng/mL) where 1 ng/mL = 2.5 nmol/L (nanomoles per litre). Total 25(OH)D (ng/mL) was 
calculated as the summation of 25(OH)D2 and 25(OH)D3. Circulating concentrations of 1,25(OH)2D (pg/mL) were measured in blood plasma using immunoassay (single batch 
of reagents) over a 2-month period, as previously described (3). Circulating concentrations of 1,25(OH)2D was measured in picomoles per liter (pmol/L) where 1 pg/mL = 2.6 
pmol/L. Measures of height, weight, weekly exercise, smoking status, alcohol consumption, family history of prostate cancer (father and brother), history of benign prostatic 
hyperplasia (BPH), diabetes, occupational social class and self-reported ethnicity were collected before receipt of the initial PSA test result, either by questionnaire or by 
nurse interview, as previously described (4). Genome-wide genotyping of participants was carried out using the Illumina Human660W-Quad_v1_A array (Illumina Inc., 
SanDiego, CA). After genotyping, quality control (QC) process was performed before imputation. We excluded individuals on the basis of the following: sex mismatches, 
minimal (<0.325) or excessive heterozygosity (>0.345), disproportionate levels of individual missingness (>3 %), cryptic relatedness measured as proportion of identity by 
descent (IBD > 0.1) and insufficient sample replication (IBD < 0.8). All individuals with non-European ancestry and SNPs with a minor allele frequency (MAF) below 1%, a call 
rate of <95% or out of Hardy-Weinberg equilibrium (p<5 x 10-7) were removed (5). All men provided written informed consent prior to inclusion in the study. Trent Multicentre 
Research Ethics Committee (MREC) approved the ProtecT study (MREC/01/4/025) and the associated ProMPT study which collected biological material (MREC/01/4/061). 
 
PRACTICAL Consortium (PRostate cancer AssoCiation group To Investigate Cancer Associated aLterations in the genome) 
The PRACTICAL consortium conducted a GWAS meta-analysis to identify SNPs associated with prostate cancer risk in analyses involving 44,825 prostate cancer cases and 
27,904 controls of European ancestry. They also conducted a GWAS to identify SNPs associated with risk of advanced prostate cancer in analyses involving 6,263 
aggressive prostate cancer cases (defined as Gleason ≥8, prostate-specific antigen (PSA) >100ng/mL, metastatic disease (M1) or death from prostate cancer) and 27,235 
controls (summary data on high-grade prostate cancer alone was not available). Full details of the individual participating studies have been published previously (6). 
Genotyping of PRACTICAL samples were performed using an Illumina Custom Infinium genotyping array (OncoArray) consisting of ~570,000 single nucleotide 
polymorphisms (SNPs) and imputed using the 1000 Genomes Project as a reference panel as previously described (7). All SNPs with poor imputation quality (r2<0.30), a 
minor allele frequency of <1%, a call rate of <98% or evidence of Hardy-Weinberg equilibrium (p<10-7 in controls or p<10-12 in cases) were removed. All studies in 
PRACTICAL have the relevant Institutional Review Board approval from each country, in accordance with the Declaration of Helsinki. 
  23 
 
IGF working group of the CHARGE consortium  
The IGF working group of the CHARGE consortium included 13 studies that participated in the GWAS for IGFBP-3 involving 18,995 participants (8,053 men and 10,942 
women) of European ancestry (8). This GWAS meta-analysis identified four SNPs (rs11977526, rs700753, rs1065656, rs4234798) that had genome-wide significant 
associations with IGFBP-3. The methods applied to measure IGFBP-3 levels differed among the participating cohorts and include enzyme-linked immunosorbent assays 
(ELISA), sandwich ELISA, coated tube immunoradiometric assays, chemiluminescent immunometric assays, radioimmunoassays (RIA) and automated two-site 
chemiluminescence immunoassay, as previously described (8). Participants were genotyped on genome-wide arrays and SNPs were imputed using the HapMap2 reference 
panel. Association analyses in individual studies were performed on IGFBP-3 levels measured in ng/mL using a multiple linear regression with an additive genetic model 
based on allele dosages adjusted for age and stratified by sex. All cohorts accounted for relatedness, population substructure using genetic principal components, study 
centre and laboratory batch of IGFBP-3 measurement where applicable. Individuals of non-European ancestry, with missing phenotype data, a diagnosis of growth hormone 
deficiency or known use of human growth hormones were excluded from the analyses (8).  
 
25(OH)D Genome Wide Association Study (GWAS) by the SUNLIGHT consortium 
The SUNLIGHT consortium included 31 studies that participated in the GWAS for 25(OH)D involving 79,366 participants of European ancestry (9). This GWAS meta-analysis 
identified six SNPs (rs8018720, rs10745742, rs10741657, rs12785878, rs3755967 and rs17216707) that had genome-wide significant associations with 25(OH)D. The 
methods applied to measure 25(OH)D levels differed among the participating cohorts and include ELISA, high performance liquid chromatography tandem mass spectrum 
(HPLC), radioimmunoassay (RIA) amd electrochemiluminescence immunoassays. Participants were genotyped on genome-wide arrays and SNPs were imputed using the 
Haplotype Reference Consortium (HRC) panel. Association analyses in individual studies were performed on natural-log transformed 25(OH)D, using a linear regression with 
an additive genetic model adjusted for month of sample collection, age, sex, body mass index and principal components (capturing genetic ancestry). To combine results 
across the contributing cohorts, a fixed effects inverse variance weighted meta-analysis was performed with control for population structure within each cohort and quality 
control thresholds of MAF>0.05, imputation info score>0.8, Hardy-Weinberg equilibrium (HWE) >1x10 and a minimum of 2 studies and 10,000 individuals contributing to each 
reported SNP-phenotype association.  
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Statistical analyses 
Observational relationship between circulating 1,25(OH)2D and IGFBP-3 levels in ProtecT  
Using data from the ProtecT study, multivariable regression analyses (with adjustment for case-control status) was employed to test observational associations between 
circulating 1,25(OH)2D with IGFBP-3 levels. Association of 1,25(OH)2D and IGFBP-3 with potential confounders and other variables (age, center, PSA levels (logged), BMI, 
smoking status, social class, history of benign hyperplasia, family history of prostate cancer and diabetes status) was also estimated using linear regression. Observational 
estimates of the SD unit change in IGFBP-3 (ng/ml) per SD unit increase in season-adjusted 1,25(OH)2D (pg/ml) were estimated using linear regression with adjustment for 
confounders (age, center, case-control status, PSA levels (logged), smoking status, social class, family history of prostate cancer, body mass index (BMI) and diabetes 
status).  
 
Causal associations between IGFBP-3 and 25(OH)D: two sample MR 
In the reverse direction, we investigated the causal effect of IGFBP-3 on 25(OH)D using the two-sample MR analyses. The SNP-exposure (IGFBP-3) and SNP-outcome 
(25(OH)D) estimates for the four IGFBP-3 associated SNPs were combined using the IVW method(10). The IVW method (similar method to that used in the two-sample MR 
analysis of IGFBP-3 and PCa) is equivalent to the two-stage least square analyses using data from ProtecT(11). As only a small number of SNPs were included in our MR 
analyses, methods to test for pleiotropy such as MR-Egger regression(11), weighted median(12) and mode method(13) were not conducted as these lack power with small 
number of SNPs.  
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